You are here: Home » Companies » Results
Business Standard

Sun Pharma logs 92% profit growth

Posts Rs 1,713 cr profit, revenue up by 25%

Topics
Sun Pharma

Aneesh Phadnis  |  Mumbai: 

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai
A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai

Sun Pharmaceutical Industries, India's largest drug maker, posted 92 per cent growth in net profit in Q4 2016 on a year-on-year basis on the basis of strong revenue growth.

Net profit for the quarter was Rs 1,713 crore as against Rs 889 crore in same period last year while revenue grew nearly 25 per cent to Rs 7634 crore. The company gained from sale of anti leukemia drug Gleevic for which it has 180 days exclusivity in the US market. Also its US subsidiary Taro posted 8.6 per cent sales growth in the March end quarter.

Sun Pharma's result however came below Bloomberg estimates on both revenue and profit.

Sun Pharma's earnings in Q4 FY 15 were impacted due to one time charges related to Ranbaxy merger and price erosion in certain products.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 31 2016. 00:38 IST
RECOMMENDED FOR YOU
.